🇺🇸 FDA
Pipeline program

NBI-1117568

NBI-1117568-SCZ3031

Phase 3 small_molecule active

Quick answer

NBI-1117568 for Schizophrenia is a Phase 3 program (small_molecule) at NEUROCRINE BIOSCIENCES INC with 5 ClinicalTrials.gov record(s).

Program details

Company
NEUROCRINE BIOSCIENCES INC
Indication
Schizophrenia
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials